P

Piramal Pharma Ltd
NSE:PPLPHARMA

Watchlist Manager
Piramal Pharma Ltd
NSE:PPLPHARMA
Watchlist
Price: 248 INR -0.34%
Market Cap: 328.8B INR
Have any thoughts about
Piramal Pharma Ltd?
Write Note

Piramal Pharma Ltd
Gain/Loss on Disposition of Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Piramal Pharma Ltd
Gain/Loss on Disposition of Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gain/Loss on Disposition of Assets CAGR 3Y CAGR 5Y CAGR 10Y
P
Piramal Pharma Ltd
NSE:PPLPHARMA
Gain/Loss on Disposition of Assets
-â‚ą4.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Gain/Loss on Disposition of Assets
â‚ą94.5m
CAGR 3-Years
111%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Piramal Pharma Ltd
Glance View

Market Cap
327.3B INR
Industry
Pharmaceuticals

Piramal Pharma Ltd. engages in development and manufacturing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 0 full-time employees. The company went IPO on 2022-10-19. The firm has approximately 15 global facilities and a global distribution network in over 100 countries. The firm's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anesthetics, injectable anti-infectives, and other therapies.

PPLPHARMA Intrinsic Value
139.65 INR
Overvaluation 44%
Intrinsic Value
Price
P

See Also

What is Piramal Pharma Ltd's Gain/Loss on Disposition of Assets?
Gain/Loss on Disposition of Assets
-4.6m INR

Based on the financial report for Mar 31, 2024, Piramal Pharma Ltd's Gain/Loss on Disposition of Assets amounts to -4.6m INR.

What is Piramal Pharma Ltd's Gain/Loss on Disposition of Assets growth rate?
Gain/Loss on Disposition of Assets CAGR 1Y
4%

Over the last year, the Gain/Loss on Disposition of Assets growth was 4%.

Back to Top